Summary & Overview
HCPCS Level II J0215: Alefacept Injection, 0.5 mg
HCPCS Level II code J0215 denotes a 0.5 mg injection of alefacept, a parenteral biologic therapy used in select immunomodulatory treatment regimens. Nationally, accurate reporting of this HCPCS Level II code supports appropriate claims processing, utilization tracking, and policy compliance for outpatient injectable therapies. The code is relevant for hospital outpatient departments, ambulatory infusion centers, and physician office settings where alefacept is administered.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical purpose and service context, an overview of payer coverage considerations, common billing modifiers, and related administrative details. The publication outlines standard billing practices for injectable biologics, notes areas where policy updates commonly affect coverage and payment, and identifies operational points for accurate service-line coding and claims submission. Data not provided in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J0215 represents an injection of alefacept, measured per 0.5 mg unit. This code is used to report administration of the biologic agent alefacept, a targeted immunomodulatory therapy administered parenterally.
-
Service type: Injectable biologic therapy
-
Typical site of service: Outpatient infusion or injection clinic; physician office or ambulatory care setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 45‑year‑old patient with moderate to severe chronic plaque psoriasis is scheduled for intramuscular or subcutaneous injection of alefacept (J0215, 0.5 mg) administered in an outpatient infusion/clinic setting. The clinical workflow begins with a dermatology or rheumatology evaluation confirming treatment candidacy, review of prior therapies and baseline laboratory screening (including CBC and liver function tests). On the day of service the patient is registered, vital signs are obtained, and informed consent for biologic therapy is documented. A clinician or trained nurse performs medication verification and reconstitution per product labeling, documents lot number and expiration, selects the appropriate injection site (typically deltoid or thigh), and administers the dose by injection. Post‑injection observation for immediate adverse reactions follows per clinic protocol (usually 15–30 minutes). Documentation includes indication, dose administered, route, site, lot number, and any modifier(s) if applicable. Billing uses HCPCS Level II code J0215 with appropriate service modifiers and payer‑specific requirements met for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |